---
layout: default
title: Anamirta Cocculus Seed Chenopodium Ambrosioides Co
parent: 僅模型預測 (L5)
nav_order: 338
evidence_level: L5
indication_count: 0
---

# Anamirta Cocculus Seed Chenopodium Ambrosioides Co
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Homeopathic Compound (Nux Vomica / Pulsatilla / Cocculus Complex): Insufficient Evidence for Repurposing Analysis

---

## One-Sentence Summary

This is a multi-ingredient homeopathic compound containing eight botanical and mineral substances — including *Strychnos nux-vomica* seed, *Pulsatilla vulgaris*, *Conium maculatum*, and *Anamirta cocculus* — with no US market authorization and no documented original indication.
TxGNN generated **no repurposing predictions** for this compound, as it lacks a DrugBank ID and cannot be anchored to the knowledge graph.
Before any repurposing analysis can proceed, foundational data collection is required.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No regulatory data on record |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | N/A — prerequisite data absent |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

TxGNN returned zero repurposing candidates for this compound. Three structural barriers explain the failure:

**1. No DrugBank ID.** The TxGNN knowledge graph uses DrugBank identifiers as the primary anchor for drug nodes. Without this anchor, no drug–target–disease links can be retrieved and no prediction score can be computed.

**2. Multi-ingredient homeopathic formulation.** The compound contains eight distinct constituents, each requiring individual mapping before any multi-target modelling can be attempted:

| Ingredient | Known Conventional Role |
|---|---|
| *Strychnos nux-vomica* seed | Contains strychnine/brucine (neurotoxic alkaloids) |
| *Pulsatilla vulgaris* | Used homeopathically for respiratory and gynaecological complaints |
| *Conium maculatum* flowering top | Contains coniine (neurotoxic alkaloid, hemlock) |
| *Anamirta cocculus* seed | Contains picrotoxin (GABA-A antagonist) |
| *Chenopodium ambrosioides* | Traditional antiparasitic herb |
| Oyster shell calcium carbonate, crude | Calcium source / homeopathic mineral |
| Phosphorus | Homeopathic mineral |
| Silicon dioxide | Excipient / homeopathic mineral |

**3. No original indication on record.** Without a known starting indication, the "from → to" repurposing pathway cannot be constructed, and the model has no disease-space anchor from which to generate candidates.

---

## Safety Considerations

No formal DDI data or package insert warnings are available for this compound. However, two ingredients warrant specific attention based on their known conventional toxicity profiles:

- **Strychnos nux-vomica seed** contains strychnine and brucine — potent convulsants at pharmacological doses.
- **Conium maculatum** (poison hemlock) contains coniine — a neurotoxic alkaloid associated with ascending paralysis.

In homeopathic preparations, these substances are typically diluted to sub-pharmacological concentrations (e.g., 6C, 30C). However, if this compound is to be investigated in any clinical setting, **dilution level (homeopathic potency) and actual ingredient concentrations must be verified** before initiating any safety or efficacy evaluation.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN pipeline returned no predictions because this compound cannot be mapped to the knowledge graph — it has no DrugBank ID, no US regulatory history, and no documented mechanism of action. The multi-ingredient homeopathic nature of the formulation adds further analytical complexity. None of the minimum prerequisites for a repurposing evaluation are currently met.

**To proceed, the following is needed:**

- [ ] Assign DrugBank IDs to each active botanical ingredient (*Strychnos nux-vomica*, *Pulsatilla vulgaris*, *Conium maculatum*, *Anamirta cocculus*, *Chenopodium ambrosioides*)
- [ ] Decide analytical strategy: evaluate as a combined formulation vs. run TxGNN separately on each ingredient and aggregate results
- [ ] Locate or reconstruct a package insert to document the original indication, dosage, and safety warnings (Data Gap DG001)
- [ ] Retrieve mechanism of action data from DrugBank for each constituent (Data Gap DG002)
- [ ] Verify homeopathic potency and confirm whether active-ingredient concentrations are sufficient for pharmacological activity — this determines whether a conventional repurposing model like TxGNN is even the appropriate analytical framework
- [ ] Re-run the full TxGNN pipeline after the above prerequisites are resolved
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

